Clinical Trial Update: Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Abiraterone Acetate tablets with ZYTIGA in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 2 | Status: COMPLETED